Study:
A Randomized Phase III Trial of ABVD Versus Stanford V(+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin`s Disease Without High Risk Features
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is
not yet known which combination chemotherapy regimen is most effective in treating Hodgkin`s
lymphoma.
Purpose:
This randomized phase III trial is studying two different combination chemotherapy
regimens and comparing how well they work, with or without radiation therapy, in treating
patients with Hodgkin`s lymphoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: bleomycin sulfate
Drug: ABVD regimen
Drug: Stanford V regimen
Drug: cyclophosphamide
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: mechlorethamine hydrochloride
Drug: prednisone
Drug: vinblastine
Drug: vincristine sulfate
Radiation: radiation therapy |
Phase 3 |
Verified by
Eastern Cooperative Oncology Group
July, 2006
Sponsored by: Eastern Cooperative Oncology Group
Information provided by: Eastern Cooperative Oncology Group
ClinicalTrials.gov identifier: NCT00003389
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Sandra J. Horning, MD., Study Chair
Richard I. Fisher, MD., Study Chair
Joseph M. Connors, MD., Study Chair
Nancy L. Bartlett, MD., Study Chair